Genitourinary Drugs Market Research Report Information by Disease (Urinary Tract Infections, Erectile Dysfunction, Hematuria, and Others), Product (Urological, Hormonal Therapy, and Others), End-User(Hospitals, Super specialty clinics) -Forecast till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Genitourinary Drugs Market, by Disease

6.1 Introduction

6.2 Urinary Tract Infections

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Urinary Incontinence & Overactive Bladder

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Kidney/Renal Cancer

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.5 Genitourinary Cancer

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.6 Bladder Cancer

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.7 Cervical Cancer

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.8 Sexually Transmitted Diseases

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.9 Interstitial Cystitis

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.10 Hematuria

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.11 Ovarian Cancer

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.12 Prostate Cancer

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.13 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Genitourinary Drugs Market, by Product

7.1 Introduction

7.2 Urologicals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Hormonal Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Gynaecologicals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5 Anti-Infectives

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.6 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Genitourinary Drugs Market, by End-User

8.1 Introduction

8.2 Hospitals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Super Specialty Centres

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.5 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Genitourinary Drugs Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Abbott

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Astellas Pharma Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 AstraZeneca

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Eli Lilly and Company

11.4.1 Company Overview

11.4.2 Technologys/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Genentech, Inc.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Immunex Corp.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 GlaxoSmithKline plc.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Ionis Pharmaceuticals

11.8.1 Overview

11.8.2 Product/ Technology Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Merck & Co., Inc.

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Novartis AG

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Bristol-Myers Squibb Company

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Antares Pharma

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Pfizer Inc.

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Bayer AG

11.14.1 Overview

11.14.2 Product Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the genitourinary drugs Industry

Chapter 13. Appendix

LIST OF TABLES

Table 1 Global Genitourinary Drugs Market Synopsis, 2020–2027

Table 2 Global Genitourinary Drugs Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Genitourinary Drugs Market, by Region, 2020–2027 (USD Million)

Table 4 Global Genitourinary Drugs Market, by Disease, 2020–2027 (USD Million)

Table 5 Global Genitourinary Drugs Market, by Product, 2020–2027 (USD Million)

Table 6 Global Genitourinary Drugs Market, by End-User, 2020–2027 (USD Million)

Table 7 North America: Genitourinary Drugs Market, by Disease, 2020–2027 (USD

Million)

Table 8 North America: Genitourinary Drugs Market, by Product, 2020–2027 (USD

Million)

Table 9 North America: Genitourinary Drugs Market, by End-User, 2020–2027 (USD

Million)

Table 10 US: Genitourinary Drugs Market, by Product, 2020–2027 (USD Million)

Table 11 US: Genitourinary Drugs Market, by Disease, 2020–2027 (USD Million)

Table 12 US: Genitourinary Drugs Market, by End-User, 2020–2027 (USD Million)

Table 13 Canada: Genitourinary Drugs Market,by Disease, 2020–2027 (USD Million)

Table 14 Canada: Genitourinary Drugs Market, by Product, 2020–2027 (USD Million)

Table 15 Canada: Genitourinary Drugs Market, by End-User, 2020–2027 (USD

Million)

Table 16 South America: Genitourinary Drugs Market, by Disease, 2020–2027 (USD

Million)

Table 17 South America: Genitourinary Drugs Market, by Product, 2020–2027 (USD

Million)

Table 18 South America: Genitourinary Drugs Market, by End-User, 2020–2027 (USD

Million)

Table 19 Europe: Genitourinary Drugs Market, by Disease, 2020–2027 (USD Million)

Table 20 Europe: Genitourinary Drugs Market, by Product, 2020–2027 (USD Million)

Table 21 Europe: Genitourinary Drugs Market, by End-User, 2020–2027 (USD Million)

Table 22 Western Europe: Genitourinary Drugs Market, by Disease, 2020–2027 (USD

Million)

Table 23 Western Europe: Genitourinary Drugs Market, by Product, 2020–2027 (USD

Million)

Table 24 Western Europe: Genitourinary Drugs Market, by End-User, 2020–2027

(USD Million)

Table 25 Eastern Europe: Genitourinary Drugs Market, by Disease, 2020–2027 (USD

Million)

Table 26 Eastern Europe: Genitourinary Drugs Market, by Product, 2020–2027 (USD

Million)

Table 27 Eastern Europe: Genitourinary Drugs Market, by End-User, 2020–2027

(USD Million)

Table 28 Asia-Pacific: Genitourinary Drugs Market, by Disease, 2020–2027 (USD

Million)

Table 29 Asia-Pacific: Genitourinary Drugs Market, by Product, 2020–2027 (USD

Million)

Table 30 Asia-Pacific: Genitourinary Drugs Market, by End-User, 2020–2027 (USD

Million)

Table 31 Middle East & Africa: Genitourinary Drugs Market, by Disease, 2020–2027

(USD Million)

Table 32 Middle East & Africa: Genitourinary Drugs Market, by Product, 2020–2027

(USD Million)

Table 33 Middle East & Africa: Genitourinary Drugs Market, by End-User, 2020–2027

(USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Genitourinary Drugs Market

Figure 3 Segmentation Market Dynamics for Global Genitourinary Drugs Market

Figure 4 Global Genitourinary Drugs Market Share, by Disease, 2020

Figure 5 Global Genitourinary Drugs Market Share, by Product, 2020

Figure 6 Global Genitourinary Drugs Market Share, by End-User, 2020

Figure 7 Global Genitourinary Drugs Market Share, by Region, 2020

Figure 8 North America: Genitourinary Drugs Market Share, by Country, 2020

Figure 9 Europe: Genitourinary Drugs Market Share, by Country, 2020

Figure 10 Asia-Pacific: Genitourinary Drugs Market Share, by Country, 2020

Figure 11 Middle East & Africa: Genitourinary Drugs Market Share, by Country, 2020

Figure 12 Global Genitourinary Drugs Market: Company Share Analysis, 2020 (%)

Figure 13 Abbott: Key Financials

Figure 14 Abbott: Segmental Revenue

Figure 15 Abbott: Geographical Revenue

Figure 16 Astellas Pharma Inc.: Key Financials

Figure 17 Astellas Pharma Inc.: Segmental Revenue

Figure 18 Astellas Pharma Inc.: Geographical Revenue

Figure 19 AstraZeneca : Key Financials

Figure 20 AstraZeneca : Segmental Revenue

Figure 21 AstraZeneca : Geographical Revenue

Figure 22 Eli Lilly and Company: Key Financials

Figure 23 Eli Lilly and Company: Segmental Revenue

Figure 24 Eli Lilly and Company: Geographical Revenue

Figure 25 Genentech, Inc.: Key Financials

Figure 26 Genentech, Inc.: Segmental Revenue

Figure 27 Genentech, Inc.. Geographical Revenue

Figure 28 Immunex Corp.: Key Financials

Figure 29 Immunex Corp.: Segmental Revenue

Figure 30 Immunex Corp.: Geographical Revenue

Figure 31 GlaxoSmithKline plc.: Key Financials

Figure 32 GlaxoSmithKline plc.: Segmental Revenue

Figure 33 GlaxoSmithKline plc.: Geographical Revenue

Figure 34 Ionis Pharmaceuticals: Key Financials

Figure 35 Ionis Pharmaceuticals: Segmental Revenue

Figure 36 Ionis Pharmaceuticals: Geographical Revenue

Figure 37 Merck & Co., Inc.: Key Financials

Figure 38 Merck & Co., Inc.: Segmental Revenue

Figure 39 Merck & Co., Inc.: Geographical Revenue

Figure 40 Novartis AG: Key Financials

Figure 41 Novartis AG: Segmental Revenue

Figure 42 Novartis AG: Geographical Revenue

Figure 43 Bristol-Myers Squibb Company: Key Financials

Figure 44 Bristol-Myers Squibb Company: Segmental Revenue

Figure 45 Bristol-Myers Squibb Company: Geographical Revenue

Figure 46 Antares Pharma: Key Financials

Figure 47 Antares Pharma: Segmental Revenue

Figure 48 Antares Pharma: Geographical Revenue

Figure 49 Pfizer Inc.: Key Financials

Figure 50 Pfizer Inc.: Segmental Revenue

Figure 51 Pfizer Inc.: Geographical Revenue

Figure 52 Bayer AG : Key Financials

Figure 53 Bayer AG : Segmental Revenue

Figure 54 Bayer AG : Geographical Revenue